PURSUING A POTENTIALLY TRANSFORMATIONAL APPROACH TO CANCER IMMUNOTHERAPY

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing.

At Allogene, we are developing a pipeline of off-the-shelf CAR T cell candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.

Allogene therapies are investigational therapies only. The safety and efficacy of allogeneic CAR T investigational therapies have not been established and these investigational therapies are not approved for commercial use by the FDA.

WE BELIEVE

The next revolution in cancer treatment is the development of AlloCAR T™ therapies engineered from the T cells of healthy donors. These off-the-shelf CAR T therapies, enhanced by gene editing, could be the next most important breakthrough in the field.

3

LOCATIONS

5

CLINICAL
CANDIDATES

13

PRECLINICAL
TARGETS

OUR MISSION

At Allogene, our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ therapies for blood cancers and solid tumors. As a team, working together, we believe we can revolutionize cancer treatment by making AlloCAR  T™ therapy a reality for patients.

OUR HISTORY

APR 2021 APR 2 0 18 SEP 2 0 18 OCT 2 0 18 DEC 2 0 18 JAN 2 0 19 Allogene acquires Pfizer’s allogeneic CAR T portfolio and closes one of the largest Series A rounds in biotechnology history— $300 million from a premier investment consortium that includes Two River, TPG, Vida Ventures, Bellco Capital, the University of California Office of the Chief Investment Officer of the Regents, Gilead, and Pfizer Public company debut, raising $372.6 million in gross proceeds in the second largest biotechnology IPO of 2018 Completes $120 million in private financing 100th employee joins FDA clears investigational new drug (IND) application, setting the stage for the Phase 1/2 ALPHA clinical trial of ALLO-501, an anti-CD19 AlloCAR T™ therapy in patients with relapsed/refractory non-Hodgkin lymphoma FEB 2 0 19 Kicks off process to build state-of-the-art AlloCAR T™ manufacturing facility in Newark, California MAY 2 0 19 MAY 2020 Presents initial Phase 1 ALLO-501 ALPHA trial data DEC 2020 Presents initial Phase 1 ALLO-715 UNIVERSAL trial data FDA clears IND applications for ALLO-316 in renal cell carcinoma and ALLO-715 in combination with nirogacestat in r/r MM Construction complete on manufacturing facility, Cell Forge 1 FDA clears IND application for ALLO-605, the first TurboCAR™ candidate for the treatment of r/r MM FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-715, an AlloCAR T™ cell therapy in development for r/r MM MAY 2021 Presents Phase 1 data on ALLO-501 and ALLO-501A Presents PK/PD data on ALLO-647 FDA clears IND application to study second indication of therapy, the UNIVERSAL study of ALLO-715, an AlloCAR T™ therapy targeting BCMA in patients with relapsed/ refractory multiple myeloma (r/r MM) JUL 2 0 21 for ALLO-605, Allogene’s first TurboCAR TM , targeting BCMA in multiple myeloma FDA clears IND application FDA grants Fast Track designation for ALLO-605 2021 FDA grants orphan drug designation for ALLO-715 AUG

OUR VALUES

At Allogene, we are committed to INNOVATE, FOCUS, COLLABORATE, and LEAD. These four values are core to our organization and how, every day, we are leading the next revolution in cell therapy.

Innovate

INNOVATE

We are rooted in science and innovative in our approach to finding better solutions for treating cancer.

Focus

FOCUS

We are focused on AlloCAR T™ therapy, our mission, and our commitment to patients.

Collaborate

COLLABORATE

We are one team collaborating toward one vision.

Lead

LEAD

We have the courage and expertise to take calculated risks in order to lead the next revolution in the treatment of cancer.

MANAGEMENT TEAM

We are led by a world-class management team of industry leaders who have unrivaled experience in the clinical development of cell immunotherapy for cancer.

Arie Belldegrun

Arie Belldegrun, MD

Executive Chairman and Co-Founder of Allogene
David Chang

David Chang, MD, PhD

President, Chief Executive Officer and Co-Founder
Alison Moore

Alison Moore, PhD

Chief Technical Officer
Barbra Sasu

Barbra Sasu, PhD

Chief Scientific Officer
Christine Cassiano

Christine Cassiano

Chief Communications Officer
Eric T. Schmidt

Eric T. Schmidt, PhD

Chief Financial Officer
Rafael G. Amado

Rafael G. Amado, MD

Executive Vice President of Research and Development and Chief Medical Officer
SusanLundeen

Susan Lundeen

Chief People Officer
Veer Bhavnagri

Veer Bhavnagri

General Counsel

BOARD OF DIRECTORS

Our Board of Directors comprises healthcare investors, academics, pharma industry veterans, and biotech entrepreneurs who have extensive expertise in gene and cell therapy. They guide our long-term strategic plan and assist in advancing our mission to lead the development of AlloCAR T™ therapies—the next revolution in cancer immunotherapy.

Arie Belldegrun, MD

Executive Chairman and Co-Founder of Allogene

David Bonderman

Chairman and Founding Partner, TPG

David Chang, MD, PhD

President, Chief Executive Officer and Co-Founder, Allogene

Debbie Messemer

Former KPMG Managing Partner

Franz B. Humer, PhD

Former Chairman and Chief Executive Officer, Roche Holding Ltd.

John DeYoung

Vice President, Worldwide Business Development, Pfizer

Joshua Kazam

Co-Founder and Partner of Two River, Co-Founder and Director of Vida Ventures, Co-Founder of Allogene

Liz Barrett

President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology

Owen Witte, MD

Professor of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles

Todd Sisitky

Managing Partner, TPG Capital

Vicki Sato, PhD

Former President of Vertex Pharmaceuticals, Former Professor, Harvard Business School and Harvard University

SCIENTIFIC ADVISORS

Our Scientific Advisory Board (SAB) comprises an accomplished group of scientific leaders who are experts in the fields of oncology, immunology, and drug discovery and development. Their strategic and scientific advice, based on vast knowledge and understanding of autologous and allogeneic similarities and differences, guides the development of our investigational AlloCAR T™ therapies for blood cancers and solid tumors.

Ton Schumacher, PhD (Chair)

Principal Investigator, Netherlands Cancer Institute

Donald B. Kohn, MD

Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Human Gene Medicine Program, University of California, Los Angeles

Jae Park, MD

Acting Chief of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center in New York

Malcolm K. Brenner, MD, PhD

Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital

Matthew Porteus, MD, PhD

Associate Professor of Pediatrics, Stanford University School of Medicine

Owen Witte, MD

Professor of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles

Stephan Grupp, MD, PhD

Professor of Pediatrics, UPenn and Section Chief of Cellular Therapy and Transplant, Children’s Hospital of Philadelphia

Stephen J. Forman, MD

Professor and Francis & Kathleen McNamara Distinguished Chair, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope Comprehensive Cancer Center

Thomas F. Gajewski, MD, PhD

Professor in Cancer Immunotherapy and Practicing Physician, University of Chicago

Wendell Lim, PhD

Professor and Chair, Department of Cellular and Molecular Pharmacology, University of California, San Francisco

OUR PARTNERS

Cellectis

We assumed Pfizer’s strategic collaboration and licensing agreement with Cellectis, with exclusive rights to develop and commercialize previously defined allogeneic CAR T therapy programs directed at select targets. We believe this alliance with Cellectis will lead to a strong pipeline of AlloCAR T™ therapies.

Notch Therapy

We have an exclusive worldwide collaboration and license agreement with Notch Therapeutics, an immune cell therapy company creating universally compatible, allogeneic T cell therapies for the treatment of diseases of high unmet need, to research and develop induced pluripotent stem cell (iPSC) AlloCAR™ therapy products for initial application in non-Hodgkin lymphoma, leukemia and multiple myeloma. Under the partnership, we plan to create allogeneic cell therapy candidates from T cells or natural killer (NK) cells using Notch’s Engineered Thymic Niche (ETN) platform.

Servier

We have a joint clinical development collaboration with Servier for UCART19, which is being developed for the treatment of adult and pediatric acute lymphoblastic leukemia (ALL). UCART19 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. We have the exclusive rights to UCART19, ALLO-501, and ALLO-501A in the United States, while Servier retains exclusive rights in all other countries.

SpringWorks

We have a clinical trial collaboration agreement with SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. This agreement will evaluate ALLO-715, our investigational anti-B-cell maturation antigen (BCMA) AlloCAR T™ therapy in combination with SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in patients with relapsed or refractory multiple myeloma.

Arie Belldegrun, MD, is the Executive Chairman and Co-Founder of Allogene. As a visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and as Co-Chairman of Breakthrough Properties, and is on the Board of Gingko Bioworks, IconOVir, ByHeart and is a Co-Founder and Senior Managing Director of Vida Ventures. Arie is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and is a member of the American Association of Genitourinary Surgeons.

David Chang, MD, PhD, is the President, Chief Executive Officer and Co-Founder of Allogene. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of YescartaTM (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, David spearheaded personalized therapy strategies underlying the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGICTM (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma. Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology and MD and PhD degrees from Stanford University. David completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.

Alison Moore, PhD, is the Chief Technical Officer for Allogene, overseeing product sciences, supply chain, manufacturing, quality and technical operations. Alison has extensive experience in all aspects of biomanufacturing and CMC product development, working in both operations and research and development. She most recently served as Senior Vice President, Process Development, at Amgen. Previously, she held senior roles at Amgen in Operations Technology, Process and Product Engineering, and Corporate Manufacturing. Prior to these positions, she was Vice President, Site Operations, at Amgen’s Fremont, Calif., manufacturing facility. Before joining Amgen, Alison was a Director in Chemistry, Manufacturing and Controls, Regulatory Affairs, at Genentech. She holds a PhD in cell biology and a bachelor’s degree in pharmacology with honors from Manchester University, England. Following her doctoral degree work there, she was a postdoctoral research fellow at the Medical University of Lübeck, Germany, and at Genentech.

Barbra Sasu, PhD, is the Chief Scientific Officer of Allogene. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a PhD from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, MD, PhD  Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immune-oncology with an emphasis on T cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immuno-oncology including the Pfizer T cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.

Christine Cassiano is the Chief Communications Officer of Allogene. She is a communications executive with wide experience in investor relations, corporate communications, media relations, brand strategy and public affairs. Christine previously served as Senior Vice President of Corporate Communications and Investor Relations for Kite until its acquisition by Gilead Sciences in 2017. Christine’s career is distinguished by the development of integrated communications strategies for companies with novel therapies such as YescartaTM (axicabtagene ciloleucel) and Botox®/Botox® Cosmetic (onabotulinumtoxinA). She has held executive management positions in international communications agencies, including roles as the Head of Healthcare for W2O and Senior Vice President and Co-Director, Healthcare, at Hill + Knowlton Strategies. Christine co-founded ARC2 Communications & Media, a boutique agency that developed groundbreaking platforms for some of the largest companies in healthcare. She has also held senior global communications roles in biotechnology and pharmaceutical companies, including Amgen, Allergan and Abraxis BioScience. Some of Christine’s career achievements include a SABRE Silver Anvil award for the launch of Botox® Cosmetic (Allergan), an In2 SABRE Award for the Most Innovative Brand/Agency Collaboration (Pfizer/ARC2), and PR Week’s 40 Under 40. Christine also serves as a Senior Strategic Advisor to Urogen Pharma, Kronos Bio and Vida Ventures. She holds a B.A. from California State University, Fullerton and Investor Relations Certification (IRC) from the University of California, Irvine.

Eric T. Schmidt, PhD, is Chief Financial Officer of Allogene. He was previously Managing Director and Senior Biotechnology Analyst at Cowen and Company. During his two decades there, he was a highly trusted industry analyst whose work was recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters and The Wall Street Journal.  Prior to joining Cowen in 1998, Eric was a Vice President and Research Analyst covering the biotechnology sector for UBS Securities. Before joining UBS, he co-founded Cambridge Biological Consultants, a scientific consulting and research firm. He holds a B.A. in chemistry from the University of Pennsylvania and a PhD in biochemistry from the Massachusetts Institute of Technology, where he serves on the Visiting Committee for the Department of Biology.

Rafael G. Amado, MD, is the Executive Vice President of Research and Development and Chief Medical Officer of Allogene. Rafael has over 15 years of biotechnology and pharmaceutical industry experience leading clinical and research teams. He most recently served as President of R&D, after serving as Chief Medical Officer, at Adaptimmune. Previously, he held several roles of increasing responsibility at GSK, most recently as Senior Vice President and Head of Oncology R&D. Prior to GSK, Rafael served as Executive Director of Therapeutic Oncology at Amgen, where he was responsible for worldwide clinical research strategy and execution and oversaw development activities for several investigational agents for molecularly characterized tumors. Before joining Amgen, he was on the faculty at the University of California, Los Angeles, most recently serving as Assistant Clinical Professor, Department of Medicine, Division of Hematology/Oncology. Rafael received an MD from the University of Seville School of Medicine and completed his internship and residency in internal medicine at Michael Reese Hospital and Medical Center, a University of Chicago-affiliated hospital. He completed a fellowship in hematology/oncology at the University of California, Los Angeles.

Susan (Susie) Lundeen, is the Chief People Officer of Allogene. Susie has held leadership roles in the full life cycle of global human resources, talent acquisition, operations, mergers and acquisition, and business expansion in several biotechnology companies. She was most recently with Unity Biotechnology where she served as Chief Human Resources Officer for six years. Prior to Unity, Susie was Senior Vice President of Human Resources at Kythera Biopharmaceuticals until its acquisition by Allergan, where she was responsible for designing and implementing all people systems supporting the company, from early product development to drug approval and eventual commercial launch. From 2005 to 2007, Susie was Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., a healthcare company that was acquired by PSS, Inc. Prior to that experience, she held various positions at Amgen, including an expatriate assignment to support the build-out of Amgen’s world-wide distribution facility in the Netherlands. She also served as Strategic HR Business Partner for Research & Development, and ultimately served as Senior Director of Human Resources responsible for Strategic Staffing and Succession Planning. Susie received a BA in Psychology and Business Administration from California Lutheran University and is a trustee on the University’s Board of Regents.

Veer Bhavnagri is the General Counsel of Allogene. He also serves as the Company’s Compliance Officer. Prior to joining Allogene, he was Vice President, Corporate Counsel, at Kite Pharma, a leader in engineered T cell therapy. Veer advised on all aspects of Kite’s business, including corporate governance, business development, compliance, SEC reporting, human resources, clinical trials, facilities, supply chain and technical and commercial operations. Veer was also an integral member of the select deal team involved in the sale of Kite to Gilead Sciences for $11.9 billion. Prior to joining Kite, Veer was a senior associate at Cooley LLP. Previously, Veer was an associate in the New York and Sydney offices of Sullivan & Cromwell LLP. Veer was a member of the Australia-based transaction team recognized as 2011 International Firm of the Year by Asian Legal Business and Australian Issuer of the Year by Insto Magazine. Veer received a J.D., magna cum laude, from The University of Michigan Law School. He received an A.B. in mathematical economics and political science, with honors, from Brown University. Veer is admitted to practice law in New York and California.

David Bonderman is Chairman and Founding Partner of TPG. He holds an undergraduate degree from the University of Washington and graduated from Harvard Law School, where he was a member of the Harvard Law Review and a Sheldon Fellow. David serves on a number of public and private Boards, including China International Capital Corporation Ltd, Cushman & Wakefield, Ryanair Holdings, plc, of which he is Chairman, The Rock and Roll Hall of Fame Foundation, the Grand Canyon Trust, and The Wilderness Society, as well as various academic and advisory boards.

Debbie Messemer has more than 30 years of experience providing financial expertise to public and private companies and was the Managing Partner of KPMG’s Bay Area and Northwest region until her recent retirement. Debbie, a certified public accountant (CPA), joined KPMG LLP, the U.S. member firm of KPMG International, in 1982 and was admitted into partnership in 1995.  As Managing Partner for the Bay Area and Northwest region, she was responsible for leading over 3,000 team members in 10 offices across all functions, including audit, tax and advisory. Debbie spent the majority of her career in KPMG’s audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to audit signing responsibilities, she has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting. Debbie is a member of the National Association of Corporate Directors (NACD) and of the San Francisco Chapter of Women Corporate Directors (WCD).  She has served extensively on non-profit and advisory boards including the Bay Area Council, the San Francisco Committee on Jobs, the California Chamber of Commerce, the San Francisco Chamber of Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San Francisco Ballet, and Posse. Debbie received a bachelor’s degree in accounting from the University of Texas at Arlington.

Franz Humer is Chairman of Neogene Therapeutics and HMNC Brain Health. He is a Board Director of Cydar and Emil Frey Holdings and an Advisor to Temasek Holdings, Letterone Healthcare and Breakthrough Properties. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its Pharmaceutical Division, progressing to become Chairman and CEO in 2001, and between 2008 and 2014 the Chairman of Roche Holding Limited. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Before joining the Roche Group, he was the managing director of Glaxo Pharmaceuticals UK and Member of the Board of Glaxo Holdings plc. He progressed to be responsible for Research, Business Development, Manufacturing, Commercial Strategy, and all non-U.S. Operations for 13 years. Before that, he held various general management positions in Latin America and Europe for Schering-Plough Corporation. He is Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. Franz earned a PhD in law from the University of Innsbruck, Austria and an MBA from INSEAD in Fontainebleau, France.

John DeYoung is Vice President of Worldwide Business Development for Pfizer Oncology. He is a member of the Oncology Leadership Team and the Worldwide Business Development Leadership Team. John joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. He received a bachelor’s degree in business from Michigan State University and an M.B.A. from the University of Chicago.

Joshua is a Co-Founder and Director of Allogene Therapeutics. Joshua Kazam is a Co-Founder and Partner of Two River, where he has served as Partner since its inception in 2004. He is a Co-Founder and Partner of Vida Ventures, LLC, a life science investment firm, and was a Co-Founder and Director of Kite Pharma, where he served on the Board of Directors from inception until its acquisition by Gilead Sciences in 2017. Joshua also serves as a Director of several privately held companies including Kronos Bio, Hubble Contacts, ByHeart Inc, and Breakthrough Properties, LLC. Joshua is a Member of the Wharton School’s Undergraduate Executive Board and serves on the Board of the Desert Flower Foundation. He received his B.S. in Economics from the Wharton School of the University of Pennsylvania.

Liz Barrett is the President and CEO of UroGen Pharma, a biotechnology company that develops and commercializes treatments for urologic and uro-oncological conditions. At UroGen, Liz spearheaded the 2020 approval of Jelmyto® for the treatment of low-grade upper tract urothelial carcinoma. She previously served as CEO of Novartis Oncology, where she managed the development and launch of the autologous CAR T therapy Kymriah® (tisagenlecleucel). Prior to her tenure at Novartis, she held several leadership positions at Pfizer, including Global President and General Manager of Oncology, and led the rollout of Ibrance®. She has also held leadership roles at Cephalon and Johnson & Johnson. Ms. Barrett currently serves on the Board of Directors of Sage Therapeutics.

Owen Witte, MD is a University Professor of Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at UCLA, where he holds the President’s Chair in Developmental Immunology at UCLA’s David Geffen School of Medicine. For 30 years, he was also an investigator with the Howard Hughes Medical Institute. Dr. Witte is also a member of the National Academy of Science and National Academy of Medicine. Dr. Witte currently serves on the Board of Directors of Allogene and previously served on the Board of Directors and the Scientific Advisory Board of Kite Pharma. He completed his postdoctoral research at the Massachusetts Institute of Technology Center for Cancer Research, working in the lab of Nobel Laureate Dr. David Baltimore. Dr. Witte also completed predoctoral research training in the lab of Dr. Irving Weissman while a medical student at Stanford University. He received his B.S. with highest honors in microbiology from Cornell University and his MD from Stanford University.

Todd Sisitsky is the Managing Partner of the TPG Capital business in the U.S. and EU, and co-leads the firm’s investment activities in the healthcare services and pharmaceutical/medical device sectors. Prior to joining TPG in 2003, Todd worked at Forstmann Little & Company and Oak Hill Capital Partners. He received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude. He has played leadership roles on TPG’s investments in Aptalis, Biomet, Fenwal, Healthscope, IASIS Healthcare, Immucor, IMS Health, Par Pharmaceutical and Surgical Care Affiliates. Todd serves on the Board of Directors for the Campaign for Tobacco-Free Kids and the Dartmouth Medical School Board of Overseers.

Vicki Sato served as President of Vertex Pharmaceuticals where she was responsible for research and development, business and corporate management, and commercial, legal and financial operations. Before joining Vertex, Dr. Sato was Vice President of Research at Biogen, Inc., where she led programs in inflammation, thrombosis, and HIV and contributed to the executive management of the company. She also served as a member of the Biogen Scientific Advisory Board. Dr. Sato began her career as a Professor in the Department of Cell and Developmental Biology at Harvard University and then returned to academia from 2006-2017 to serve as a Professor of the Practice in Molecular and Cell Biology at Harvard University and a Professor of Management Practice at Harvard Business School. Dr. Sato is currently on the Board of Directors at Denali Therapeutics, Vir Biotechnology and Akouos.

Ton Schumacher, PhD serves as Senior Member at the Netherlands Cancer Institute in Amsterdam and Professor of Immunotechnology at Leiden University Medical Center. He completed his PhD at The Netherlands Cancer Institute where he studied the interactions of MHC class I molecules with antigenic peptides in the laboratory of Dr. Hidde Ploegh. After completing a postdoctoral fellowship in Dr. Ploegh’s lab at the Massachusetts Institute of Technology, he joined the group of Dr. Peter Kim at the Whitehead Institute in Cambridge, Mass. Ton later returned to the Netherlands Cancer Institute to study the development of tumor-specific T cell immunity through biotechnological approaches. Ton is a recipient of, among others, the Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, San Salvatore Award, Meyenburg Cancer Research Award, and William B. Coley Award, and is founder of three biotechnology companies in the area of immuno-oncology.

Donald B. Kohn, MD, is Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, Director of the UCLA Human Gene and Stem Cell Therapy Program, and a member of the Broad Stem Cell Research Center and the Jonsson Comprehensive Cancer Center. He received a B.S in biology and an M.S. in microbiology from the University of Illinois-Urbana and an MD from the University of Wisconsin-Madison. Donald completed a pediatric internship and residency at the University of Wisconsin Hospitals and a medical staff fellowship in the Metabolism Branch of the National Cancer Institute. He was at Children’s Hospital Los Angeles, USC Keck School of Medicine for 21 years, where he rose to the rank of professor and served as Head of the Division of Research Immunology/Bone Marrow Transplantation. Donald previously served as President of the American Society of Gene and Cell Therapy and the Clinical Immunology Society. Donald is the recipient of an Elizabeth Glaser Scientist Award from the Pediatric AIDS Foundation, a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Lifetime Achievement Award.

Dr. Jae Park is Associate Attending Physician in the Division of Hematologic Oncology, Leukemia Service, a Director of Adult Acute Lymphoblastic Leukemia Program and the Acting Chief of Cellular Therapeutics Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Park received his medical degree from the Johns Hopkins School of Medicine, and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Park has written numerous peer-reviewed articles appearing in New England Journal of MedicineScience Translational MedicineBloodCancer Discovery and Journal of Clinical Oncology. His research – which focuses on translating and establishing novel targeted and immunotherapies for patients with hematologic malignancies – has been recognized and funded by the The American Society of Hematology, The American Association for Cancer Research, The American Society of Clinical Oncology, The Leukemia and Lymphoma Society, The Geoffrey Beene Research Foundation, and The National Comprehensive Cancer Network. Widely recognized as one of the world experts in cell therapies, Dr. Park is the leading principal investigator of several clinical trials in patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Dr. Brenner is the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine and founding director of the Center for Cell and Gene Therapy at the Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital. As a professor at Baylor College of Medicine, Dr. Brenner’s expertise spans cell and gene therapy, molecular and human genetics, pediatrics, and translational biology & molecular medicine. His primary research interest is the use of gene transfer to augment the immune response to human tumors, using vaccines and adoptive transfer of genetically modified T cells. Dr. Brenner is also member of the National Academy of Medicine. Dr. Brenner holds a PhD from the University of Cambridge, a M.B.Ch.B. from Westminster Medical College, and a B.S. from the University of Cambridge.

Matthew Porteus, MD, PhD is an Associate Professor of Pediatrics in the Department of Pediatrics, Divisions of Hematology/Oncology and Human Gene Therapy at Stanford University School of Medicine. He completed his combined MD/PhD at Stanford, with his PhD focused on understanding the molecular basis of mammalian forebrain development. After completing his dual degree program, Matthew completed an internship and residency in pediatrics at Boston Children’s Hospital and a pediatric hematology/oncology fellowship in the combined Boston Children’s Hospital/Dana Farber Cancer Institute program. For his fellowship and postdoctoral research, he worked with Nobel Laureate Dr. David Baltimore at the Massachusetts Institute of Technology and Caltech where he began his studies in developing homologous recombination as a strategy to correct disease-causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, Matthew took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before returning to Stanford as an Associate Professor.

Stephan Grupp, MD, PhD is the Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Section Chief of Cellular Therapy and Transplant, Director of the Cancer Immunotherapy Program, and Medical Director of the Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia. Over 200 scientific publications have been generated by Dr. Grupp’s research, and he has received numerous achievement and impact awards for his contributions to the cell therapy and oncology fields, including election to the National Academy of Medicine. Dr. Grupp has extensive experience with cell therapy clinical development and commercialization, having led all of the pediatric/young adult ALL trials leading to the first FDA (and now international) approval of a CAR T therapy. He received his MD and PhD from the University of Cincinnati College of Medicine and completed fellowship training at Harvard Medical School, Boston Children’s Hospital, Dana Farber Cancer Institute and Brigham and Women’s Hospital.

Dr. Forman is the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and Director of the T Cell Therapeutics Research Laboratory at the City of Hope Comprehensive Cancer Center. An expert in leukemia, lymphoma and bone marrow transplantation, Dr. Forman has served at City of Hope for more than 40 years, deeply involved with the translational and clinical research at City of Hope’s Toni Stephenson Lymphoma Center, Center for CAR T Cell Therapy, Judy and Bernard Briskin Center for Multiple Myeloma Research and the Gehr Family Center for Leukemia Research. Dr. Forman was recognized by the American Society for Blood and Marrow Transplantation as the 2019 E. Donnall Thomas Lecturer, and awarded the 2019 DKMS Mechtild Harf Science Award. Dr. Forman holds an MD from the University of Southern California and a B.A. from St. John’s College.

Thomas F. Gajewski, MD, PhD is a Professor of medicine and pathology at the University of Chicago as well as a practicing physician specializing in hematology and oncology. Throughout his career, Dr. Gajewski has focused on understanding fundamental aspects of anti-tumor immunity and bringing these concepts forward from the laboratory into clinical trials. An author of more than 250 manuscripts, 20 book chapters, and speaker at over 200 scientific conferences, Dr. Gajewski is the founding editor of the Journal for Immunotherapy of Cancer. He has served as past president of the Society for Immunotherapy of Cancer, past chair of the Cancer Immunopathology and Immunotherapy grant review study section at the National Institutes of Health, served on the program committees for the American Society of Clinical Oncology and the American Association for Cancer Research, and is a grant reviewer for the Melanoma Research Alliance and Cancer Research Institute. He received a BS, PhD in Immunology, and MD degrees from the University of Chicago.

Wendell Lim is the Byers Distinguished Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco, and an Investigator of the Howard Hughes Medical Institute. He received his A.B. in Chemistry, summa cum laude, from Harvard College, his PhD in Biochemistry and Biophysics at the Massachusetts Institute of Technology and completed his postdoctoral training at Yale University. His research focuses on the design principles of molecular circuits that govern cell decision-making and responses. His lab has made contributions in understanding the molecular machinery of cell signaling and how molecular modules have been used in evolution to build novel new behaviors. Most recently he has been a pioneer in the emerging field of synthetic biology, exploring how these design principles can be harnessed to engineer cells with customized therapeutic response programs. He is an author of the textbook, Cell Signaling (Garland Science 2014) and was the founder of the cell therapy biotech startup, Cell Design Labs, which was acquired by Gilead Sciences in 2017.